{'fraction_non_alphanumeric': 0.032590051457975985, 'fraction_numerical': 0.02058319039451115, 'mean_word_length': 5.5195530726256985, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Autologous bone marrow rescue in the treatment of advanced tumors of childhood

High‐dose multiagent chemotherapy followed by autologous marrow rescue was used in the treatment of 13 patients with Stage III or IV childhood tumors. Encouraging results are being obtained in abdominal lymphoma (1/3 complete remissions (CR)); rhabdomyosarcoma (2/4 CR); and retinoblastoma (1/2 CR). In neuroblastoma, the results are disappointing, with only one of four patients in CR; this patient developed a lymphoma associated with Epstein‐Barr virus infection. Marrow reconstitution was obtained in 11 patients, with recovery of neutrophils to >0.5 × 109/liter between six and 30 days and platelet recovery to >50 × 109/liter between seven and 38 days. Investigations on the numbers of cells or committed granulocyte precursors (CFU‐c's) infused and parameters of hematologic recovery show poor correlation and suggest that a more accurate and reliable assay for the predictability of cryopreserved marrow to reconstitute marrow function within a reasonable time is necessary. Nonhematologic toxicities of high‐dose multiagent chemotherapy are the principal dose‐limiting factors.